+234 8034 523 190

Posttransplant lenalidomide can slow down multiple myeloma

A phase 3 study has demonstrated that maintenance therapy with the oral drug lenalidomide (Revlimid) is associated with significantly improved progression-free and overall survival in patients with newly diagnosed myeloma who have undergone autologous hematopoietic stem-cell transplantation. “The results of this trial will change our treatment of multiple myeloma patients,” predicted Thomas Shea, MD, director...
Read More